Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy

Han,Yiqun; Zhang,Peng; Chen,Yuanyuan; Sun,Jiping; Kong,Fansheng

doi:10.3892/ijmm.2014.1770

Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy

Authors:
- Yiqun Han
- Peng Zhang
- Yuanyuan Chen
- Jiping Sun
- Fansheng Kong
View Affiliations

Affiliations: Department of Respiratory Medicine, General Hospital of Ji'nan Command of Chinese PLA, Ji'nan, Shandong 250031, P.R. China, Department of Hematology, General Hospital of Ji'nan Command of Chinese PLA, Ji'nan, Shandong 250031, P.R. China
Published online on: May 6, 2014 https://doi.org/10.3892/ijmm.2014.1770
Pages: 191-196

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The co-delivery of DNA and antitumor drugs has the potential to treat cancer. In this study, we aimed to develop surface-modified, co-encapsulated solid lipid nanoparticles (SLN) containing enhanced green fluorescence protein plasmid (pEGFP) and doxorubicin (DOX) in order to create a multifunctional delivery system that targets lung cancer cells, in an effort to improve the efficacy of cancer therapy. DOX- and pEGFP-loaded SLN were prepared separately and then mixed to form co-encapsulated SLN (SLN/DE). Transferrin (Tf)-containing ligands were used for the surface coating of the vectors. The in vitro transfection efficiency of the modified vectors was evaluated using a human alveolar adenocarcinoma cell line (A549 cells) and the in vivo transfection efficiency of the modified vectors was evaluated using mice bearing A549 tumors. The Tf-modified DOX and pEGFP co-encapsulated SLN (T-SLN/DE) had a particle size of 267 nm with a 42 mV surface charge. The in vitro cytotoxicity of T-SLN/DE was low (cell viability was between 80 and 100% compared with the controls). T-SLN/DE displayed a remarkable therapeutic effect both in drug delivery and gene therapy. In conclusion, our results demonstrate that the multifunctional delivery system can improve the efficacy of cancer therapy through the combination of gene therapy and chemotherapy. In addition, the coating of active targeting ligands can improve the efficacy of the carriers at targeting lung cancer cells. Thus, the novel gene and drug delivery system offers an effective strategy for lung cancer gene therapy.

View Figures

View References

1	Shepherd FA, Bunn PA and Paz-Ares L: Lung cancer in 2013: state of the art therapy for metastatic disease. Am Soc Clin Oncol Educ Book. 339–346. 2013. View Article : Google Scholar : PubMed/NCBI
2	Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati BK and Kompella UB: Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 15:7299–7308. 2009. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Ward E, Brawley O and Jamel A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
4	Kawabata A, Baoum A, Ohta N, Jacquez S, Seo GM, Berkland C and Tamura M: Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth. Cancer Res. 72:2057–2067. 2012. View Article : Google Scholar : PubMed/NCBI
5	Bajelan E, Haeri A, Vali AM, Ostad SN and Dadashzadeh S: Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. J Pharm Pharm Sci. 15:568–582. 2012.PubMed/NCBI
6	Brannon-Peppas L and Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 56:1649–1659. 2004. View Article : Google Scholar : PubMed/NCBI
7	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
8	Liu C, Liu F, Feng L, Li M, Zhang J and Zhang N: The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles. Biomaterials. 34:2547–2564. 2013. View Article : Google Scholar : PubMed/NCBI
9	Zheng C, Zheng M, Gong P, Deng J, Yi H, Zhang P, Zhang Y, Liu P, Ma Y and Cai L: Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. Biomaterials. 34:3431–3438. 2013. View Article : Google Scholar : PubMed/NCBI
10	Loh XJ, Ong SJ, Tung YT and Choo HT: Co-delivery of drug and DNA from cationic dual-responsive micelles derived from poly(DMAEMA-co-PPGMA). Mater Sci Eng C Mater Biol Appl. 33:4545–4550. 2013. View Article : Google Scholar : PubMed/NCBI
11	Zhao J, Mi Y and Feng SS: Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials. 34:3411–3421. 2013. View Article : Google Scholar : PubMed/NCBI
12	Shim G, Han SE, Yu YH, et al: Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J Control Release. 155:60–66. 2011. View Article : Google Scholar : PubMed/NCBI
13	Xu Z, Zhang Z, Chen Y, Chen L, Lin L and Li Y: The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model. Biomaterials. 31:916–922. 2010. View Article : Google Scholar : PubMed/NCBI
14	Qiu B, Ji M, Song X, et al: Co-delivery of docetaxel and endostatin by a biodegradable nanoparticle for the synergistic treatment of cervical cancer. Nanoscale Res Lett. 7:6662012. View Article : Google Scholar : PubMed/NCBI
15	Kaneshiro TL and Lu ZR: Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials. 30:5660–5666. 2009. View Article : Google Scholar : PubMed/NCBI
16	Jiang Z, Sun C, Yin Z, Zhou F, Ge L, Liu X and Kong F: Comparison of two kinds of nanomedicine for targeted gene therapy: premodified or postmodified gene delivery systems. Int J Nanomedicine. 7:2019–2031. 2012. View Article : Google Scholar : PubMed/NCBI
17	Wang W, Zhou F, Ge L, Liu X and Kong F: Transferrin-PEG-PE modified dexamethasone conjugated cationic lipid carrier mediated gene delivery system for tumor-targeted transfection. Int J Nanomedicine. 7:2513–2522. 2012.
18	Kong F, Ge L, Liu X, Huang N and Zhou F: Mannan-modified PLGA nanoparticles for targeted gene delivery. Int J Photoenergy. 2012:9267542012. View Article : Google Scholar
19	Kong F, Zhou F, Ge L, Liu X and Wang Y: Mannosylated liposomes for targeted gene delivery. Int J Nanomedicine. 7:1079–1089. 2012. View Article : Google Scholar
20	Olbrich C, Bakowsky U, Lehr CM, Müller RH and Kneuer C: Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release. 77:345–355. 2011. View Article : Google Scholar : PubMed/NCBI
21	Vighi E, Ruozi B, Montanari M, Battini R and Leo E: Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid. Eur J Pharm Biopharm. 67:320–328. 2007. View Article : Google Scholar
22	Bellocq NC, Pun SH, Jensen GS and Davis ME: Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem. 14:1122–1132. 2003. View Article : Google Scholar : PubMed/NCBI
23	Li H and Qian ZM: Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev. 22:225–250. 2002. View Article : Google Scholar : PubMed/NCBI
24	Maruyama K: Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev. 63:161–169. 2011. View Article : Google Scholar : PubMed/NCBI
25	Torchilin VP: Multifunctional nanocarriers. Adv Drug Deliv Rev. 58:1532–1555. 2006. View Article : Google Scholar : PubMed/NCBI
26	Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 4:145–160. 2005. View Article : Google Scholar : PubMed/NCBI
27	Lukyanov AN, Gao Z, Mazzola L and Torchilin VP: Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res. 19:1424–1429. 2002. View Article : Google Scholar : PubMed/NCBI
28	Miao J, Du YZ, Yuan H, Zhang XG and Hu FQ: Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf B Biointerfaces. 110:74–80. 2013. View Article : Google Scholar : PubMed/NCBI
29	Gao X, Wang B, Wei X, et al: Preparation, characterization and application of star-shaped PCL/PEG micelles for the delivery of doxorubicin in the treatment of colon cancer. Int J Nanomedicine. 8:971–982. 2013. View Article : Google Scholar : PubMed/NCBI
30	Men K, Liu W, Li L, et al: Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system. Nanoscale. 4:6425–6433. 2012. View Article : Google Scholar : PubMed/NCBI
31	Wang BL, Gao X, Men K, et al: Treating acute cystitis with biodegradable micelle-encapsulated quercetin. Int J Nanomedicine. 7:2239–2247. 2012.PubMed/NCBI
32	Li P, Liu D, Miao L, Liu C, Sun X, Liu Y and Zhang N: A pH-sensitive multifunctional gene carrier assembled via layer-by-layer technique for efficient gene delivery. Int J Nanomedicine. 7:925–939. 2012.PubMed/NCBI
33	Jia Y, Yuan M, Yuan H, et al: Co-encapsulation of magnetic Fe₃O₄ nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery. Int J Nanomedicine. 7:1697–1708. 2012.PubMed/NCBI
34	He SN, Li YL, Yan JJ, Zhang W, Du YZ, Yu HY, Hu FQ and Yuan H: Ternary nanoparticles composed of cationic solid lipid nanoparticles, protamine, and DNA for gene delivery. Int J Nanomedicine. 8:2859–2869. 2013.PubMed/NCBI
35	Mehnert W and Mäder K: Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 47:165–196. 2001. View Article : Google Scholar : PubMed/NCBI
36	Singh M: Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr Pharm Des. 5:443–451. 1999.PubMed/NCBI